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Abstract: Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting the 
reproductive, metabolic and psychological health of women. Clinic-based studies indicate that sleep 
disturbances and disorders including obstructive sleep apnea and excessive daytime sleepiness occur 
more frequently among women with PCOS compared to comparison groups without the syndrome. 
Evidence from the few available population-based studies is supportive. Women with PCOS tend 
to be overweight/obese, but this only partly accounts for their sleep problems as associations are 
generally upheld after adjustment for body mass index; sleep problems also occur in women with 
PCOS of  normal weight. There are several, possibly bidirectional, pathways through which PCOS 
is associated with sleep disturbances. The pathophysiology of PCOS involves hyperandrogenemia, a 
form of insulin resistance unique to affected women, and possible changes in cortisol and melatonin 
secretion, arguably reflecting altered hypothalamic–pituitary–adrenal function. Psychological and 
behavioral pathways are also likely to play a role, as anxiety and depression, smoking, alcohol use 
and lack of physical activity are also common among women with PCOS, partly in response to the 
distressing symptoms they experience. The specific impact of sleep disturbances on the health of 
women with PCOS is not yet clear; however, both PCOS and sleep disturbances are associated with 
deterioration in cardiometabolic health in the longer term and increased risk of type 2 diabetes. Both 
immediate quality of life and longer-term health of women with PCOS are likely to benefit from 
diagnosis and management of sleep disorders as part of interdisciplinary health care.
Keywords: polycystic ovary syndrome, sleep, sleep disturbance, hypothalamic-pituitary-adrenal, 
cardiometabolic health
Introduction
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder with implications 
for reproductive, psychological and metabolic health. Despite first being identified 
in the 1930s, recognition of an association between PCOS and sleep disturbances 
is relatively recent. A search of the PubMed database indicates that the majority of 
research on this topic has been published after 2005 and the body of work remains 
quite small (Figure 1).
In this review, we first provide an overview of PCOS and summarize the clinical 
and epidemiological literature pertaining to sleep disturbances and disorders among 
women with the condition. The pathways through which PCOS may influence sleep 
are then described in detail, focusing on the endocrine, psychosocial and behavioral 
characteristics that are often present among women with PCOS, drawing attention to 
probable bidirectional relationships (Figure 2). Current knowledge about the  long-term 
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Figure 1 The number of articles published in PubMed per year on the topic of PCOS and sleep.








































































































Figure 2 Summary of the bidirectional pathways through which PCOS interacts with sleep disturbances, with potentially detrimental effects on long-term cardiometabolic 
health.













consequences of PCOS for cardiometabolic health is outlined 
as well as the potential contribution of impaired sleep to 
deterioration of health profiles.
Polycystic ovary syndrome
PCOS is an endocrine disorder that manifests in an array 
of symptoms that varies from one woman to another.1 This 
heterogeneity has hampered the definition of the syndrome, 
etiological research, recognition in clinical practice and 
appropriate treatment and support for women.
PCOS was first recognized as a clinical entity in the 1930s. 
At that time it was named Stein–Leventhal syndrome, after 
the two clinicians who first reported the disorder in seven 
women who presented with hirsutism, amenorrhea and 
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enlarged  bilateral polycystic ovaries, along with obesity.2,3 
Once considered a reproductive disorder acquired by adult 
women, it is now widely accepted that PCOS is a lifelong 
metabolic condition.4
Features of the syndrome classically emerge during 
puberty, but diagnosis can be difficult because irregular men-
struation is common in normal development.1,5 Excess body 
hair accumulates gradually, reflecting increasing duration 
of androgen exposure. Some girls (and women) with PCOS 
have severe acne vulgaris (predominantly on the lower face, 
neck, chest and upper back).1
Historically, recognition of PCOS by clinicians was 
erratic.6,7 In addition, reluctance to seek medical advice 
(e.g. due to embarrassment) meant that many women did 
not receive a diagnosis until they sought fertility treatment, 
or lifelong.8 Undiagnosed PCOS is still relatively common.9
Currently, there are three sets of criteria for diagnosing 
PCOS, summarized in Figure 3. Differences between the 
criteria reflect controversy about the pathogenesis of PCOS 
and the different forums in which experts’ opinions were 
canvassed.3 In 1990, experts at a conference sponsored by 
the US National Institutes of Health (NIH) produced the 
first attempt at defining PCOS clinically. The NIH criteria 
specify (in order of importance) that clinical and/or bio-
chemical signs of hyperandrogenism should be present as 
well as oligo- or anovulation (i.e. irregular or no periods).10 
In 2003, the European Society of Human Reproduction and 
Embryology and the American Society for Reproductive 
Medicine produced a statement, known as the Rotterdam 
criteria, specifying that two out of the following three must 
be met for a diagnosis of PCOS: clinical and/or biochemical 
hyperandrogenism, oligo- or anovulation and polycystic ova-
ries on ultrasound.11 In 2006, the Androgen Excess Society 
(AES) Taskforce produced criteria specifying that hyperan-
drogenism must be present for diagnosis, in  addition to either 
oligo- or anovulation or polycystic ovaries on ultrasound 
(or both).12 There have been several attempts to subclassify 
the syndrome using clinical and metabolic criteria, without 
universal agreement.3,13
All diagnostic criteria specify that diagnosis of PCOS 
should only be made after exclusion of other endocrine dis-
orders including congenital adrenal hyperplasia, androgen-
secreting tumors, Cushing’s syndrome, thyroid dysfunction 
and hyperprolactinemia. Early studies of women with PCOS 
suggested they had elevated prolactin, and explored overlap 
in symptoms between hyperprolactinemia and PCOS, but 
these are now considered to be two distinct conditions.14–18
Beyond the enlargement of ovaries originally noted by 
Stein and Leventhal,2 ovaries with multiple cysts (follicles 
with arrested development) have other features, including a 
thickened covering capsule and greatly increased stromal tis-
sue. The thecal and stromal layers produce excess androgen, 
and this led to the view that pathogenesis is primarily ovar-
ian.19 While recognizing wider metabolic involvement, the 
AES takes the position that PCOS is primarily a disorder of 
hyperandrogenism.12 Lack of consensus on this matter per-
sists because hormone signaling has a major role in systems 
such as the hypothalamic–pituitary–adrenal (HPA) axis, so 
the disorder could have a central origin, and there are con-
flicting results from interventions in which androgens were 
Figure 3 A summary of the three sets of criteria for the diagnosis of PCOS: the National institutes of Health criteria (1990),10 the Rotterdam criteria (2003)11 and the 
Androgen excess Society criteria (2006).12
















National Institutes of Health criteria Rotterdam criteria Androgen Excess Society criteria
Any two of three
Polycystic ovaries
Excluding other endocrine disorders
e.g. congenital adrenal hyperplasia, androgen-secreting tumors, Cushing’s syndrome, thyroid dysfunction, hyperprolactinemia





reduced in women with PCOS.3 Additionally, constructive 
debate is impeded by lack of a reliable assay designed to 
measure androgens in the range relevant to women, approxi-
mately one-tenth that of men.20,21
Research undertaken in the 1980s demonstrated insulin 
resistance in women with PCOS, underpinning the alternative 
view that this is the cardinal feature of the syndrome, with 
hyperinsulinemia causing hyperandrogenemia and anovula-
tion.3 Even lean women with PCOS generally have insulin 
resistance of an intrinsic form,22 which appears to be the result 
of a defect in post-binding insulin signaling that disturbs 
metabolic but not mitogenic functions.23 This abnormality 
appears unique to PCOS, as it has not been observed in 
other conditions of insulin resistance, including obesity and 
type 2 diabetes.24 Thus, when women with PCOS have high 
body weight, they are affected by both intrinsic and extrinsic 
insulin resistance.3 PCOS has recently been conceptualized 
as a condition of severe metabolic stress,25 a position that 
we support as it provides a way to account for the pervasive 
molecular and biochemical derangements that occur in PCOS 
and variation in symptom profiles.
Clustering of diagnosed PCOS and isolated hormonal 
and metabolic symptoms within families supports a genetic 
component to the etiology of PCOS;26 however, phenotypic 
variation suggests that multiple genes are involved.27 Familial 
and cohort studies have identified numerous gene loci as can-
didates for conferring susceptibility to PCOS. These include 
polymorphisms in loci associated with androgen receptors 
and with insulin signaling. For many of the candidate loci, 
it remains unclear as to how they relate to specific PCOS 
characteristics.27
Support for fetal or early life origins of PCOS stems from 
animal models in which exposure to androgen excess, or 
growth restriction or acceleration, has produced symptoms 
of PCOS.3,28 It is unlikely that maternal androgens reach the 
fetus in human pregnancies, although fetal ovarian androgen 
production is possible.3 Birth phenotypes in humans have 
consistently been associated with insulin resistance, type 2 
diabetes and the metabolic syndrome.29–32
While we accept a genetic contribution, our research33,34 is 
premised on interactions with the fetal environment produc-
ing epigenetic changes that culminate in PCOS.35 Hypoth-
esized “programming” of metabolic function is not simply 
about growth of the fetus or size at birth, although these are 
overt signs of perturbed development in utero.36 A range of 
conditions, including maternal under- and overnutrition and 
mental distress, can inhibit the activity of an enzyme in the 
placenta (11 beta-hydroxysteroid dehydrogenase) that is 
 critical to reducing fetal exposure to maternal glucocorti-
coids.37 Through this process, it is proposed that overexposure 
of the fetus alters the set points and function of the HPA axis, 
with profound implications for metabolism.
Uncertainties about PCOS also persist because it is dif-
ficult to study in representative population-based samples of 
women. Obtaining self-reports of doctor-diagnosed PCOS 
will result in misclassification of a substantial proportion 
of women as unaffected. Some symptoms can be reported 
reliably but others require invasive tests, and the sensitive 
nature of symptoms may affect participation. Thus, few stud-
ies with community-based samples have been undertaken to 
date, although clinic-based samples have been reported on 
extensively.
We retrospectively established a birth cohort of Austra-
lian women using records from a large maternity hospital.9 
We traced over 90% of 2199 female babies three decades 
after they were born. Around half of the young women who 
were eligible joined the study and completed an initial inter-
view in which medical and reproductive history, including 
symptoms of PCOS, were reported. Women were asked to 
provide a blood sample for assessment of free testosterone. 
Those with evidence of both hyperandrogenism and oligo- or 
anovulation were classified as having PCOS as per the NIH 
criteria. Women with one or both of those two symptoms were 
referred to a clinic for ovarian ultrasound so that we could 
apply the Rotterdam criteria. The prevalence of PCOS was 
8.7 ± 2.0% with NIH criteria, 11.9 ± 2.4% with Rotterdam 
criteria assuming those who did not consent to ultrasound 
did not have cystic ovaries and 17.8 ± 2.8% with Rotterdam 
criteria using multiple imputation for missing ultrasound 
data. Over two-thirds of those classified as having PCOS 
had not been diagnosed previously.
Sleep disturbances and disorders 
and PCOS
Sleep disturbances include altered sleep duration, delay of 
sleep onset, difficulty in maintaining sleep or awakening 
early.38 Insomnia is defined as impairment in the ability to 
initiate or maintain sleep, including extended periods of 
wakefulness during the night. Chronic insomnia disorder 
is diagnosed when insomnia occurs at least three nights 
per week and for at least three months.39 Obstructive sleep 
apnea (OSA) is characterized by frequent cessations of 
breathing during sleep and may occur along with other sleep 
disturbances.40 Clinically, OSA is diagnosed by detecting 
the frequency of events that are apneic (no airflow for 10 
seconds) and hypopneic (decreased airflow for 10 seconds 
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associated with either an oxyhemoglobin desaturation or 
an arousal detected by electroencephalography), as per the 
apnea–hypopnea index (AHI). A diagnosis of OSA is made 
when AHI is ≥15 or when AHI is ≥5 with symptoms such 
as daytime sleepiness, loud snoring and witnessed breathing 
interruptions.41
Sleep disturbances and disorders have repercussions for 
daytime mood, cognition and psychomotor functioning,42 
which acutely affect well-being and daily activities, and 
can inhibit performance in roles such as that of parent or 
employee.43,44 Aspects of cognition that appear most affected 
are attention, executive function and working memory,42,45 
with significant implications for productivity.44 Fatigue, atten-
tion deficits and psychomotor impairment can affect safety, 
increasing the risk of workplace and motor vehicle acci-
dents.42 Thus, poor sleep represents a serious health problem.
As mentioned, it is difficult to study PCOS in representa-
tive population-based samples; so evidence concerning the 
prevalence of sleep disturbances and disorders across the full 
spectrum of PCOS severity is limited. We identified only three 
such studies (Table 1), summarized here, each supporting an 
excess of sleep disturbances and disorders in women with 
PCOS that was not accounted for by obesity.
Two studies have drawn on the Taiwan National Health 
Insurance Research Database in which PCOS and sleep 
Table 1 Summary of population- and community-based studies of sleep disturbances and PCOS in women
Study, country Study design Study groups Outcomes of 
interest
Key results













onset sleep disorders: 
iCD-9 780.5 
(insomnias) and 307.4 
(difficulty initiating 
and maintaining sleep, 
excluding OSA)
•	 women with PCOS were more likely to be diagnosed 
with sleep disorders: HR = 1.495 (95% Ci 1.176–1.899)
•	 Most developed in the first year since diagnosis of PCOS
Lin et al,46 
Taiwan
4595 with PCOS 
and 4595 without 
PCOS matched 
for age and time 
of enrollment
Diagnosis of OSA 
during follow-up (2–13 
years)
•	 women with PCOS had a greater incidence of OSA 
(1.71 vs 0.63 per 1000 person-years)
•	 HR = 2.63 (95% Ci 1.57–4.04) adjusted for demographics 
(urbanization, income) and comorbidities (hypertension, 
dyslipidemia, diabetes, obesity)
Moran et al,48 
Australia
Cross-sectional 
analysis of data from 
a cohort based on 
births (1973–1975) 
at a large maternity 
hospital
87 with PCOS 






•	 Any sleep disturbances two times higher in women with 
PCOS
•	 Difficulty falling asleep: OR = 1.94 (95% Ci 1.28–2.95), 
attenuated but still significant after adjusting for BMI and 
depressive symptoms
•	 Difficulty maintaining sleep: OR = 1.92 (95% Ci 
1.12–3.31), mediated by BMi and depressive symptoms
•	 PCOS not associated with early awakening or daytime 
sleepiness
Abbreviations: BMI, body mass index; CI, confidence interval; HR, hazard ratio; ICD-9, International Classification of Diseases, Ninth Revision; OR, odds ratio; OSA, 
obstructive sleep apnea; PCOS, polycystic ovary syndrome.
disorders were recorded using International Classification 
of Diseases codes (and thus required recognition and for-
mal diagnosis).46 In a longitudinal design, data for women 
with PCOS (n = 4595) and a comparison group of women 
matched for age (n = 4595) were assembled over 2–8 years. 
Women with PCOS had greater incidence of OSA (1.71 vs 
0.63 per 1000 person-years), a difference not due to obesity 
or demographic characteristics (adjusted hazard ratio [HR] 
= 2.6, 95% confidence interval [CI] 1.6–4.0). In the second 
study, sleep disorders excluding OSA were considered as part 
of an investigation of PCOS and psychiatric disorders.47 Over 
a 10-year period, compared to an age-matched comparison 
group of women (n = 21,724), those with PCOS (n = 5431) 
were 50% more likely to be diagnosed with a sleep disorder 
(HR = 1.5, 95% CI 1.2–1.9).
In the community-based cohort of Australian women that 
we undertook, sleep disturbances were self-reported using a 
modified version of the Jenkins questionnaire,48 by 87 women 
with PCOS (as per Rotterdam criteria) and 637 women of 
similar age.48 Sleep disturbances, specifically difficulty fall-
ing asleep (odds ratio [OR] = 1.9, 95% CI 1.3–3.0) and dif-
ficulty maintaining sleep (OR = 1.9, 95% CI 1.1–3.3), were 
twice as common in women with PCOS compared to those 
without. The former association persisted after accounting 
for body mass index (BMI) and depressive symptoms, but 





Table 2 Summary of clinic-based studies of sleep disturbances and PCOS in women
Study, country Study 
design
Study groups Outcomes of interest Key results





18 with PCOS, 
all obese; and 18 
without PCOS 
matched for age and 
weight
AHi, AHi (ReM sleep), 
OSA (AHi >5 with eDS), 
eSS, sleep onset latency, 
sleep efficiency, % stages 3 
and 4 and % ReM sleep
•	 AHi: PCOS 22.5 ± 6.0 vs controls 6.7 ± 1.0,  
p = 0.008
•	 AHi (ReM sleep): PCOS 41.3 ± 7.5 vs controls 13.5 
± 3.3, p < 0.01
•	 OSA: PCOS 44.4% vs controls 5.5%, p = 0.008
•	 eSS: PCOS 9.5 ± 0.9 vs non-PCOS 5.8 ± 0.8,  
p < 0.01
•	 No significant differences in other PSG variables







95 with PCOS and 95 
without PCOS
AiS, iSi, eSS and PSQi •	 Clinically significant insomnia was higher in PCOS
o	 AiS – 12.6% vs 3.2%, p = 0.01
o	 iSi – 10.5% vs 1.1%, p = 0.004
•	 No significant difference in ESS or PSQI










Snoring, RDi, OSA (RDi 
≥5) and other variables (e.g. 
arterial oxygen saturation)
•	 16/23 (69.6%) met the criteria for OSA
•	 5/23 required CPAP
•	 No correlation was found between degree of 
obesity and severity of OSA
•	 No results reported for other variables







17 with PCOS, all 
nonobese; 27 with 
PCOS, all obese; 
26 without PCOS, 
all nonobese; and 8 
without PCOS, all 
obese
Berlin questionnaire for 
assessment of OSA risk
•	 women with PCOS had higher prevalence of high-
risk OSA (47% vs 15%, p < 0.01)
•	 None of the nonobese PCOS and nonobese control 
women screened positive for OSA
•	 Obese PCOS vs obese controls had similar 
prevalence of OSA
•	 BMi was only independent predictors of OSA
(Continued)
not the latter. PCOS was not observed to be associated with 
unintended early morning waking or daytime sleepiness.48
Clinic-based studies of sleep disturbances 
in women with PCOS
Polysomnographic assessments of clinical samples of women 
with PCOS have been undertaken, with OSA the focus in the 
majority (summarized in Table 2). Interpretation of the find-
ings of these studies should be tempered with understanding 
of the limitations of this literature: clinic-based samples of 
women with PCOS are likely to comprise women with the 
most severe symptoms;49 comparison groups are often conve-
nience samples of women attending clinics for reasons other 
than PCOS; and sample sizes are often modest.
OSA is common in clinical samples of women with 
PCOS, affecting 17–75%, substantially higher than in other 
women of similar age and BMI, and thus is not attributable 
to the tendency of women with PCOS to be obese.50–54 One 
study has shown that OSA is elevated in women who have 
BMI in the normal range along with PCOS.54 Women with 
PCOS have consistently been shown to have elevated AHI, 
regardless of OSA diagnosis.50,51,53–55 Few differences in other 
polysomnographic variables, such as sleep latency, sleep effi-
ciency and waking after sleep onset, have been found.50,51,54,55
We have not systematically attended to studies of adoles-
cents, given the difficulty in diagnosing PCOS at that stage 
of development and the likelihood that selection procedures 
(including factors involved in seeking an early diagnosis) 
contribute to inconsistent findings in polysomnographic 
 studies.56–58 Of interest, however, one study demonstrated 
higher AHI and more OSA among obese girls with PCOS 
(n = 28) referred to a sleep clinic compared with a control 
group of girls (n = 28) matched for age and BMI, but no dif-
ferences from a control group of boys (n = 28).59
Excessive daytime sleepiness (EDS) is a hallmark of sleep 
disturbance in men, but may not be as relevant to women60 
who are more likely to report low mood or irritability or 
morning headaches following poor sleep.48,61 Nevertheless, 
EDS in women with PCOS has been investigated,50,51,54,55 usu-
ally using the Epworth Sleepiness Scale.50,51,55 Predominantly, 
the clinical studies have shown PCOS to be associated with 
EDS, often in the absence of OSA. For example, in one study 
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Study, country Study 
design
Study groups Outcomes of interest Key results





50 with PCOS, all 
untreated; and 16 
without PCOS, 
matched for age, who 
reported snoring
RDi, SDB (RDi ≥5 with 
symptoms, RDi >15 
without symptoms), sleep 
onset, TST, wASO, ReM 
sleep (minutes), NReM 
sleep (minutes), sleep 
efficiency, ESS and RERA
•	 SDB: OR = 46.5 (95% Ci 14.6–148.4), no longer 
significant after adjusting for BMI and WC
•	 Higher RDi in PCOS with SDB (22.5) compared to 
controls with SDB (9.0), p = 0.01
•	 wASO: PCOS 55.4 ± 57.9 vs non-PCOS 30.5 ± 
26.4, p = 0.025
•	 eSS: PCOS 12.5 ± 3.2 vs non-PCOS 9.32 ± 1.7,  
p < 0.001
•	 No other significant differences in PSG variables









eSS, PSQi and Berlin 
questionnaire
•	 62.5% had poor sleep quality (PSQi >5)
•	 45% had chronic daytime sleepiness (eSS score ≥10)
•	 75% had high risk of OSA by Berlin questionnaire
8 with PCOS, 
referred for PSG; 
and 8 without PCOS, 
matched for age, 
nonobese
Sleep efficiency, sleep 
latency, TST, TwT, ReM 
sleep (minutes) and NReM 
sleep (minutes)
Measures of sleep efficiency in PCOS vs controls
•	 PCOS women had significantly lower sleep 
efficiency and REM and NREM sleep compared to 
controls
•	 PCOS women had significantly higher sleep latency, 
TwT and TST compared to controls
Severity of SDB measured 
using AHi, MAi and ODi 
during total, ReM and 
NReM sleep and minimum 
oxygen saturation
Measures of SDB severity in PCOS women
•	 AHi total (mean ± Se) = 7.0 ± 1.2
•	 MAi total (mean ± Se) = 17.6 ± 1.8
•	 ODi total (mean ± Se) = 10.8 ± 2.2
•	 Minimum oxygen saturation (%) = 80.6 ± 1.6
•	 All values were higher during ReM than NReM sleep





52 with PCOS; and 
21 without PCOS, 
matched for age and 
BMi
AHi, OSA (AHi >5), TST, 
MAi and minimum oxygen 
saturation
•	 OSA: adjusted OR = 7.1 (95% Ci 1.7–45.7), adjusted 
for age, BMi and ethnicity 
•	 Presence of OSA associated with significantly higher 
MAi and minimum oxygen saturation among PCOS 
group. Data not presented for four control women 
with OSA
•	 No significant difference in TST







53 with PCOS, all 
premenopausal; and 
452 without PCOS
Sleep apnea (AHi ≥10 
with clinical symptoms), 
upper airway resistance 
syndrome, SDB, eDS, sleep 
latency (minutes), wASO, 
total wake time, % sleep 
time, % stage 1, % stage 2, 
% SwS and % ReM sleep
•	 Sleep apnea: OR = 28.7 (95% Ci 4.9–294.4)
•	 Upper airway resistance syndrome: OR = 27.6 (95% 
Ci 2.1–1423.0)
•	 SDB (all): OR = 30.6 (95% Ci 7.2–139.4)
•	 SDB (BMi ≥32.3): OR = 5.1 (95% Ci 1.1–31.3)
•	 eDS (BMi <32.2): OR = 10.3 (95% Ci 2.5–60.0)
•	 eDS (BMi ≥32.2): OR = 3.8 (95% Ci 1.4–11.6)
•	 No significant differences in other PSG variables







18 with PCOS, 
all nonobese and 
untreated; 10 without 
PCOS, matched for 
age and BMi
AHi (total, NReM sleep, 
ReM sleep), ARi (total, 
NReM sleep, ReM sleep, 
spontaneous, PLM-related), 
PLM, ESS, sleep efficiency, 
sleep latency, % ReM sleep 
and ReM sleep latency
•	 Mean total AHi: PCOS 0.79 ± 0.21 vs non-PCOS 
0.29 ± 0.09, p = 0.041
•	 Mean AHi (NReM sleep): PCOS 0.57 ± 0.19 vs non-
PCOS 0.03 ± 0.03, p = 0.014
•	 No significant differences in other PSG variables
•	 None of the women in the study had AHi >5
Note: Sleep efficiency = TST/TiB.
Abbreviations: AHI, apnea–hypopnea index; AIS, Athens Insomnia Scale; ARI, arousal index; BMI, body mass index; CI, confidence interval; CPAP, continuous positive 
airway pressure; eDS, excessive daytime sleepiness; eSS, epworth Sleepiness Scale; iSi, insomnia Severity index; MAi, microarousal index; NReM, non-rapid eye movement; 
ODi, oxygen desaturation index; OR, odds ratio; OSA, obstructive sleep apnea; PCOS, polycystic ovary syndrome; PLM, periodic limb movement; PSG, polysomnography; 
PSQi, Pittsburgh Sleep Quality index; RDi, respiratory distress index; ReM, rapid eye movement; ReRA, respiratory effort-related arousal; SDB, sleep-disordered breathing; 
Se, standard error; SwS, slow-wave sleep; TiB, time in bed (minutes); TST, total sleep time (minutes); TwT, total wake time (minutes); wASO, wake after sleep onset 
(minutes); wC, waist circumference.
Table 2 (Continued)





80% of women with PCOS (n = 53) complained of EDS but 
only 17% were diagnosed with OSA.54
Insomnia in women with PCOS has received very little 
attention. Among a clinical sample of Polish women with 
PCOS (n = 95), 13% had insomnia according to the Athens 
Insomnia Scale and 10% according to the Insomnia Severity 
Index (ISI), with corresponding proportions among controls 
(n = 130) of 3% and 1%, respectively.62
How pathophysiology of PCOS is 
linked to sleep disturbances
Since PCOS is characterized by metabolic disturbances, and 
as the endocrine system has an important role in governing the 
sleep–wake cycle, it is likely that PCOS interferes with arousal 
and sleep or that there is a more complex interrelationship.
The sleep–wake cycle in humans is driven by the interac-
tion between two processes, Process S, which is sleep promot-
ing, and Process C, which promotes wakefulness.63 Process 
S represents the homeostatic need for sleep and accumulates 
over the time spent awake. Process C is regulated by the circa-
dian system and ensures that sleep and wakefulness coincide 
with environmental light–dark stimuli.64 The circadian system 
is coordinated centrally by the suprachiasmatic nucleus in 
the hypothalamus and is synchronized with environmental 
stimuli.65 The suprachiasmatic nucleus relays circadian infor-
mation to other areas of the brain, such as the pituitary and 
pineal pineal glands, and to peripheral tissues via the regula-
tion of clock-gene expression and neuroendocrine signaling.66
Melatonin and cortisol play important roles in regulating 
sleep and wakefulness. Melatonin, secreted by the pineal 
gland, is increased at night and decreased during the day, thus 
communicating light–dark information.64,67 Cortisol, which 
is secreted from the adrenal cortex and regulated by the HPA 
axis, also follows a circadian pattern, steadily increasing 
during sleep and peaking in the morning.67,68
As illustrated in Figure 2, there are several pathways 
through which PCOS and sleep disturbances may be associ-
ated. The pathways outlined here have been identified based 
on the endocrine profiles of women with PCOS, the unique 
stressors they experience, and related psychological and 
behavioral factors.
Obesity
Obesity is common in women with PCOS and exacerbates 
the metabolic stress that we and others view as central to 
pathogenesis of the syndrome.25 In a meta-analysis of mainly 
clinic-based samples (n = 35 studies),69 49% of women with 
PCOS were classified as obese (95% CI 42–55%) and 54% 
had central adiposity (95% CI 43–62%). The proportions were 
around twofold higher than among comparison groups (obesity: 
relative risk [RR] = 2.8, 95% CI 1.9–4.1; central adiposity: 
RR = 1.7, 95% CI 1.3–2.3). These proportions should not be 
interpreted as prevalence estimates for all women with PCOS 
because obesity has been shown to be more common (and 
more extreme) in clinical samples than in community-based 
studies.49 For example, in the Australian Longitudinal Study 
on Women’s Health (overall n = 9145), at wave 4, 478 women 
reported having received a diagnosis of PCOS and, on average, 
had moderately higher BMI (mean difference 2.5 kg/m2, 95% 
CI 1.9–3.1) and moderately greater longitudinal weight gain 
over a 10-year period (mean difference 2.6 kg kg/m2, 95% CI 
1.2–4.0) compared to their peers.70
Variation in BMI among women with PCOS appears to 
be related to factors such as age and ethnicity and possibly 
to severity of the syndrome.69 It is not clear why women with 
PCOS are predisposed to obesity, nor whether it reflects physi-
ology or psychology. Some literature suggests that appetite 
and satiety are altered in PCOS, with affected women report-
ing higher postprandial hunger and lower satiety after a test 
meal compared to other women.71 Underlying postprandial 
suppression of gut hormones such as ghrelin, cholecystoki-
nin, glucagon-like peptide 1 and peptide YY may occur in 
PCOS.71–74 Alternatively or additionally, obesity may reflect 
abnormalities in energy expenditure as women with PCOS 
have been found to have reduced resting metabolic rate (1659 
kJ/day)75 and reduced thermic effect of food (42 kJ/meal, 
equivalent to weight gain of 1.9 kg/year).76 Psychological 
factors are consistent correlates of poor weight manage-
ment;77 as will be described presently, women with PCOS have 
relatively more anxiety and depression, and relatively poor 
self-esteem, body image and quality of life (QoL), compared 
to their peers.78
Obesity is one of the strongest risk factors for OSA,79 attrib-
utable to anatomical changes of the upper airways and thoracic 
region.80 Longitudinal studies of men and women demonstrate 
that a 10% increase in body weight predicts a sixfold increase 
in risk of developing moderate-to-severe sleep-disordered 
 breathing.81 When obesity is severe (BMI >40 kg/m2), the 
prevalence of OSA in men and women is as great as 92%.82
There is evidence that obesity contributes to sleep distur-
bances beyond OSA.83 Several studies have shown that obesity 
is associated with objectively assessed daytime sleepiness and 
subjective reports of fatigue, independently of OSA.84,85 Vgont-
zas et al83 have proposed two possible mechanisms through 
which obesity produces these sleep disturbances. In one 
pathway, shorter sleep duration and subjective fatigue in obese 
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individuals is related to psychological distress and upregulation 
of the HPA axis. In the second pathway, in which sleep duration 
is not altered, metabolic parameters such as insulin resistance 
as well as lack of physical activity are invoked, with normal- or 
downregulation of the HPA axis. Both pathways are proposed 
to be associated with hypercytokinemia.83
There is some evidence that obesity directly contributes 
to OSA among women with PCOS, although, as highlighted 
previously, it does not fully account for findings from com-
munity- and clinic-based studies. For example, high BMI 
in women with PCOS (n = 53) has been associated with 
elevated risk of OSA and daytime sleepiness.54 In a study of 
women with (n = 44) and without (n = 34) PCOS, obesity 
was the strongest predictor of sleep apnea risk (as measured 
by the Berlin questionnaire),86 in contrast to another study 
of obese women with PCOS (n = 23), among whom there 
was no relationship between the degree of obesity and sleep 
apnea severity (as per AHI).87
On balance, the evidence supports contributions to sleep 
disorders both of PCOS and obesity. From the perspective of 
stress, the former is metabolic while the latter is oxidative, 
which might aggravate sleep harmonically,25 but studies that 
examine this are lacking.
Hyperandrogenemia
The prevalence of OSA differs by sex, with obese women 
having lower risk compared to males of similar BMI.88 Men 
and women often have different clinical presentations for 
OSA. For example, when matched for age, BMI, AHI and 
EDS score, women were less likely than men to present with 
witnessed apnea but more likely to report insomnia.89 Dif-
ferences between men and women may be due to differences 
in the anatomy of the upper airway, sex hormones and/or 
central adiposity.90,91
Women with PCOS commonly have increased testoster-
one (free and bound) and androstenedione, and hyperandro-
genemia is a diagnostic criterion. Excess androgen is known 
to induce changes in body composition, including increased 
central adiposity. In women with PCOS, serum androgen lev-
els are positively correlated with waist–hip ratio, independent 
of obesity.92 Androgen-induced changes to central adiposity, 
rather than increased weight overall, may contribute to OSA 
in these women.
This proposition is supported by work showing that 
among obese women with PCOS (n = 18), the severity of 
OSA was correlated with both the degree of androgen excess 
and waist–hip ratio.50 Similarly, among nonobese women 
with (n = 18) and without (n = 10) PCOS, who did not have 
OSA, AHI during non-rapid eye movement (NREM) sleep 
was correlated with total testosterone.55 An inconsistent 
finding has been reported for a group of women with PCOS 
(n = 44) in whom risk of OSA was determined by the Berlin 
questionnaire.86
Few studies have investigated the potential role of hyper-
androgenemia in other forms of sleep disturbance in women. 
Mixed findings about androgens and sleep architecture have 
been reported from polysomnographic studies of adolescent 
girls with PCOS.56,93
insulin resistance
There is considerable evidence for a relationship between 
sleep disturbances and insulin resistance, with numerous 
studies demonstrating that sleep restriction and/or sleep 
disorders can exacerbate insulin resistance.94–96 Insulin 
resistance may also have a role in the development of sleep 
disturbances. For example, in a cross-sectional study of risk 
factors for EDS (n = 1741) undertaken in the US, diabetes 
(fasting glucose >126 mg/dL) was strongly associated 
with EDS.84 Similarly, in a small study of men with OSA, 
those with EDS (n = 22) had higher plasma insulin levels 
and insulin resistance compared with those without EDS 
(n = 22) when matched for age, BMI, and AHI.97 A prospec-
tive study of incident OSA in a population-based sample of 
French men and women (n = 3565) also demonstrated that 
fasting hyperinsulinemia predicted development of OSA, 
independently of BMI.98
The mechanisms by which insulin resistance may lead to 
OSA or EDS are unknown. Evidence from animal and human 
studies has demonstrated that insulin increases sympathetic 
outflow,99,100 which may in turn affect sleep architecture and 
the risk of sleep-disordered breathing and daytime sleepiness.
In a polysomnographic study of women with (n = 53) and 
without (n = 452) PCOS, Vgontzas et al found that insulin 
resistance was the strongest risk factor for sleep apnea, before 
and after controlling for age, BMI, and free and total testoster-
one levels.54 Similar findings were reported in another study 
of women with PCOS (n = 40), with higher fasting insulin 
levels observed among those with elevated risk of OSA (as 
per Berlin questionnaire).52
If insulin resistance causes sleep disturbances, then 
treatment with insulin sensitizers should be mitigating. Ado-
lescent girls with PCOS who received metformin treatment 
reported reduced sleep disturbances and daytime sleepi-
ness, but it is not possible to distinguish between effects of 
improved insulin resistance and the concomitant reductions 
in BMI and hyperandrogenemia.101 In a recent pilot for a 





randomized placebo-controlled trial, nondiabetic individuals 
with insulin resistance and OSA (n = 45) were allocated to 
receive either pioglitazone or placebo. Pioglitazone produced 
no improvement in OSA symptoms or other measures of sleep 
quality, despite significant improvements in insulin sensitiv-
ity.102 Thus, there is insufficient evidence to draw conclusions 
about this matter, and we recommend further research.
Cortisol
In a recent longitudinal study of obese girls aged 13–16 
years with (n = 20) and without PCOS (n = 20), the role of 
the steroid metabolome was investigated. No difference in 
morning cortisol concentration was found between the two 
groups, although levels were twice as high as those reported 
in studies of girls of normal weight.103 Furthermore, weight 
loss was associated with a decrease in cortisol whether or not 
the girls had PCOS. Together, this suggests that the adrenal 
stimulation was attributable to obesity rather than to PCOS.
Findings concerning women with PCOS are somewhat 
contradictory. In one study (n = 21 with PCOS, 11 over-
weight/obese; n = 10 without PCOS, none overweight/obese), 
24-hour cortisol profiles were obtained. While there was no 
difference in mean 24-hour cortisol levels overall, women 
with PCOS had lower night-time cortisol levels compared 
to controls, and this was most pronounced for the women 
with PCOS who were not overweight/obese.104 In another 
study, evening, but not morning, plasma cortisol levels were 
higher in women with PCOS (n = 40) compared to women 
of similar age and BMI without PCOS (n = 55).105 It is pos-
sible that elevated cortisol levels among women with PCOS 
reflect high BMI, as one study showed that concentration and 
profiles of cortisol excretion were similar for obese women 
with (n = 15) and without (n = 15) PCOS.106
Complete HPA function in women with PCOS has not 
been described. Any changes – whether due to PCOS or 
associated obesity – are relevant, as dysfunction of the HPA 
axis at any level impacts on sleep, including increased sleep 
fragmentation, decreased slow wave sleep, and shortened 
sleep time.107
There is evidence that women with PCOS have a height-
ened physiological response to emotional stress. When 
exposed to an experimental stressor, women with PCOS 
(n = 32) had higher levels of adrenocorticotropic hormone 
immediately and 15 minutes post-stress, and higher serum 
cortisol level 15 minutes post-stress, compared to women 
without PCOS (n = 32), matched for age and BMI. This was 
despite the emotional response (state anxiety) reported by 
the two groups being similar.108
Sleep deprivation is itself a stressor and is associated 
with elevated cortisol levels.109 It is therefore possible that 
a bidirectional relationship exists between stress-related 
hyperactivity of the HPA axis and sleep disturbances in 
women with PCOS.110
Melatonin
A study of melatonin secretion over 24 hours in women with 
PCOS has not been undertaken. Melatonin from a single 
blood sample taken between midnight and 4 am was higher 
among women with PCOS (n = 50) compared to controls 
(n = 50).111 Two studies have demonstrated elevated 24-hour 
urinary 6-sulphatoxymelatonin (the primary metabolite of 
melatonin) in women with PCOS (n = 22 in the first and 
n = 24 in the second study) compared to controls (n = 35 
and n = 26, respectively).112,113
However, the changes in melatonin described in women 
with PCOS are unlikely to result in the profound sleep 
disturbances that have been reported in this subpopulation, 
particularly given 6-sulphatoxymelatonin was not found to 
be correlated with sleep efficiency.113 A strong correlation 
between melatonin obtained from a single blood sample (as 
above) and testosterone was found in women with PCOS,111 
and melatonin was reduced after hyperandrogenemia 
was attenuated by cyproterone acetate-ethinyl estradiol 
treatment.114 This suggests that elevated melatonin levels 
described in women with PCOS may be a result of androgen 
excess. Conversely, chronic administration of melatonin to 
women with PCOS (2 mg per day for six months) signifi-
cantly decreased testosterone levels and reduced menstrual 
irregularities,115 suggesting that supraphysiological levels of 
melatonin can reduce androgen levels.
Psychosocial aspects of PCOS and 
association with sleep
A number of psychosocial aspects of PCOS are likely to 
contribute to sleep disorders and disturbances in affected 
women. These are summarized in Figure 4.
Mental health profiles of women with 
PCOS
Anxiety and depression are well recognized to be associ-
ated with sleep disorders.116–118 A systematic review of nine 
longitudinal studies found suggestive, though not definitive, 
evidence of a bidirectional relationship.119 A recent study 
of young women (n = 171) followed over two weeks found 
reciprocal dynamics between anhedonic depression and 
disrupted sleep to be especially potent.120
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Anxiety and depression are elevated in women with 
PCOS, with consistent evidence presented in several sys-
tematic reviews with meta-analysis.121–125 In our community-
based sample, among women with PCOS (the majority 
of whom had not previously been diagnosed), 50% had 
symptoms consistent with clinical depression (Center for 
Epidemiologic Studies Depression Scale) compared with 
30% of their peers.48
In one of the above systematic reviews,125 clinical 
symptoms, including hirsutism, obesity, and infertility, 
were shown to contribute to higher emotional distress in 
women with PCOS, but did not fully account for the dispar-
ity. Elevated androgens have been associated with negative 
affect and depressive symptoms in women with PCOS,78,126 
but the relationship between androgens and mood disorders 
in women remains controversial.124,127 As discussed, women 
with PCOS may have hyperresponsivity of the HPA axis, 
which is associated with impaired mental health, including 
depression.128
In the community-based cohort of Australian women that 
we undertook, as mentioned, difficulty falling asleep and dif-
ficulty maintaining sleep were twice as common in women 
with PCOS compared to peers of similar age.48 Depressive 
symptoms mediated both associations, but to varying degrees.
In a clinical sample of women with PCOS (n = 114), 
those with a history of depression had a threefold increase 
in disturbed sleep (as per the Patient Health Question-
naire).129 In another study, women with (n = 30) and without 
PCOS (n = 30), matched for age and BMI, were recruited 
by advertisement in a Swedish community.130 Symptoms of 
anxiety and depression were self-reported (using subscales 
of the Comprehensive Psychopathological Rating Scale for 
Affective Syndromes). Over 60% of women with PCOS had 
anxiety symptoms above a cut-point corresponding to clini-
cal relevance, compared to 13% of controls, with the specific 
symptom of reduced sleep prominent.
As with anxiety and depression, it is likely that 
a  bidirectional relationship exists between sleep and 
Figure 4 Summary of psychosocial and behavioral factors that are common among women with PCOS and their potential contribution to sleep disturbances and disorders.
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QoL.131 This may be especially so in people with medical 
conditions.132
QoL for girls and women with PCOS appears to be poorer 
than for their peers, although less is known about this than 
about specific conditions such as depression and anxiety. A 
systematic review and meta-analysis of five studies showed 
that women with PCOS had lower scores than their counter-
parts on all domains assessed by the Short Form-36 Health 
Survey, including physical and social function.133 A recent 
systematic review134 of QoL in adolescents and young women 
with PCOS identified nine studies that were too diverse in 
approach for meta-analysis to be performed. However, all 
studies reported a negative association between PCOS and 
QoL, with body weight issues conspicuous.
Distressing symptoms of PCOS are likely to contribute 
to poor QoL. In women more broadly, a systematic review 
with meta-analysis has demonstrated the profound impact of 
infertility on QoL.135 Other stressors experienced by women 
with PCOS – that have received less attention – may con-
tribute, including negative body image, poor self-esteem, 
poor sexual relations, reduced social support and low social 
engagement.136–138
Lifestyle and health behaviors
Lifestyle factors and health behaviors, including smok-
ing, consumption of alcohol and lack of physical activity, 
can contribute to impaired sleep. Tobacco smoking has 
been associated with altered sleep architecture, short sleep 
duration and poor-quality sleep, based on both self-reports 
and polysomnography.139,140 In nonalcoholics, the effect of 
alcohol consumption on sleep varies during the night, at 
first decreasing sleep latency and increasing the quality and 
quantity of NREM sleep, then as alcohol is metabolized, 
reducing NREM and fragmenting sleep.140,141 Alcohol is also 
associated with exacerbation of snoring and OSA.140 Physi-
cal inactivity has been associated with reduced self-reported 
hours of sleep142 and increased risk of clinically diagnosed 
insomnia.143  Furthermore, there is evidence that increased 
physical activity improves sleep quality.144,145
There is some evidence that lifestyles and behaviors of 
women with PCOS are less healthy than those of other women 
of similar age and socioeconomic status. For example, in a 
case series of women with PCOS presenting at a reproductive 
health clinic, around half smoked cigarettes, substantially 
more than expected based on their demographic profile.146 
Consistent with this, in the US 2002 National Health Interview 
Survey, women who reported menstrual-related problems 
were shown to be more likely than others to smoke and drink 
heavily.147
Women with PCOS are less physically active than other 
women and may have difficulty in sustaining engagement in 
physical activity over the long term.148 When interventions to 
improve physical activity among women with PCOS have been 
trialed, attrition rates have been high.149 Barriers contributing 
to low physical activity in women with PCOS include lack of 
confidence in the ability to maintain activity, fear of injury 
and physical limitations.148 It is also possible that there are 
physiological reasons for impaired exercise capacity in women 
with PCOS. For example, it has been shown that sedentary 
normal-weight women with PCOS (n = 14) have impaired 
cardiorespiratory capacity (maximal oxygen consumption 
and submaximal ventilatory thresholds) compared to age- and 
BMI-matched sedentary women without PCOS (n = 14).150
Long-term cardiometabolic 
consequences of sleep disturbances 
in PCOS
There are few long-term studies of women with PCOS, with 
information especially lacking after menopause. However, 
available evidence suggests that women with PCOS may 
have relatively early onset of type 2 diabetes and other 
cardiometabolic disorders. This is not accounted for by the 
higher prevalence of obesity among women with PCOS, as 
highlighted in the studies described here. Drawing on wider 
literature, it is possible that sleep disorders may contribute 
to deterioration in the heath of women with PCOS, although 
this has not been studied directly.
Detailed cardiovascular profiles of around 1000 women 
were obtained across 20 years in the CARDIA (Coronary 
Artery Risk Development in Young Adults) study undertaken 
in the US, commencing when participants were aged 18–30 
years. Information on PCOS symptoms obtained 16 years 
from baseline was combined with androgen data from year 
2 to classify women as having PCOS or not. Using data from 
year 5, women with PCOS (n = 42) had higher left ventricular 
mass index and larger left arterial diameter.151 By year 16, 
when women were aged 34–46 years, PCOS was associated 
with a twofold increase in incident diabetes (with almost 
a quarter of women with PCOS affected) and a twofold 
increase in dyslipidemia. Among women with normal BMI, 
those with PCOS (n = 31) had three times the rate of diabetes 
compared to those without PCOS.152 At year 20, women with 
PCOS (n = 55) had increased coronary artery calcification 
and intima-media thickness.153
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Australian hospital admission data from 1980 to 2011 
have been used to compare 2566 women with a recorded 
diagnosis of PCOS to 25,660 age-matched women (identified 
using the electoral roll); most women in this study were aged 
under 40 years. Women with a diagnosis of PCOS were two 
to three times more likely to be hospitalized for adult-onset 
diabetes, hypertensive disorders, ischemic heart disease and 
cerebrovascular disease compared to women without PCOS. 
These findings remained statistically significant after adjust-
ing for obesity.154
In a retrospective cohort study, women with PCOS 
(n = 319) identified through hospital records were compared 
with age-matched women (n = 1060) identified through 
general practice records. After an average follow-up of 31 
years, when approximately 80% of women were postmeno-
pausal, those with PCOS had elevated prevalence of diabetes, 
hypertension and high cholesterol.155 Another study with a 
small sample size and substantial losses to follow-up over 
21 years found more hypertension and higher triglycerides 
in women with PCOS (n = 25 of 35) compared to women of 
similar age and BMI (n = 68 of 120).156
Turning to the wider literature, a recent meta-analysis 
of cohort studies showed that OSA was associated with 
increased risk of type 2 diabetes after adjustment for age, 
sex and BMI (RR = 1.49, 95% CI 1.27–1.75, eight studies, 
63,647 participants).157 Other types of sleep disturbance were 
also associated with type 2 diabetes, notably – in view of our 
findings on women with PCOS48 – difficulty initiating sleep 
(RR = 1.55, 95% CI 1.23–1.95) and difficulty maintaining 
sleep (RR = 1.72, 95% CI 1.45–2.05).
Sleep restriction has been demonstrated to result in 
increased food intake due to increased appetite, exceeding the 
energy amount needed to meet the requirements of extended 
wakefulness, and thereby resulting in weight gain.158–160 It has 
also been shown to decrease the ability to lose body fat with 
dietary restriction,158,161 and to alter glucose metabolism, with 
decreases in glucose clearance, insulin sensitivity and acute 
insulin response documented.158,162,163
OSA is likely to increase the risk of diabetes through 
intermittent hypoxia and arousals, which result in impaired 
glucose tolerance through increasing sympathetic nervous 
system activity, HPA axis dysregulation, altered cytokine 
release and oxidative stress.164–167 OSA is also independently 
associated with hypertension, premature atherosclerosis and 
arterial stiffness and an increased risk of future myocardial 
infarction, stroke and cardiovascular mortality.166,168,169 This 
may be due to the combination of sympathetic nervous 
system stimulation and endothelial dysfunction that result 
from OSA.170,171
In studies of short duration, insulin–glucose metabolism 
and lipids are worse in women with PCOS who have OSA 
than among women with PCOS but not OSA, independent 
of BMI.52,54,59,172 A link between sleep disturbances and poor 
long-term cardiometabolic health among women with PCOS 
remains speculative, as direct evidence is lacking.
Management of sleep disturbances 
in PCOS
Referral to a sleep specialist allows diagnosis of clinical con-
ditions such as OSA and insomnia, and subsequent treatment. 
OSA is generally diagnosed using overnight polysomnogra-
phy to generate AHI.40 Insomnia diagnosis ideally requires 
assessment by a clinical psychologist.173 However, many 
sleep medicine clinics do not currently have the resources 
necessary for adequate diagnosis, such as the ISI question-
naire, sleep diaries and measures of daytime fatigue without 
sleepiness. It important to recognize that OSA and insomnia 
are frequently comorbid,173 and also that women with PCOS 
may have other forms of sleep disturbance.
Weight loss is generally recommended for overweight 
and obese people with OSA,40 although recent research has 
indicated that weight loss may only decrease the severity 
of OSA in a minority of patients.174 As described above, 
weight loss may be particularly difficult to achieve in many 
women with PCOS due to hormonal abnormalities and other 
factors. Weight loss in women with PCOS would improve 
insulin sensitivity and symptom profiles, including fertility, 
so research is needed to understand the type and intensity of 
support required to achieve this. Avoidance of alcohol and 
sedative medications, which may predispose the upper air-
way to collapse, is also frequently recommended for OSA.40 
Again, this poses a particular difficulty for women with 
PCOS in view of their anxiety and use of alcohol, possibly 
as a coping mechanism.175
In cases of mild OSA, oral appliances, commonly known 
as mandibular advancement splints, which are custom-made 
to increase upper airway size and reduce the likelihood of 
airway collapse during sleep, may be recommended.40 How-
ever, efficacy and acceptability of oral appliances in women 
with PCOS is yet to be explored.
A small amount of research has been conducted in women 
with PCOS about the benefits of continuous positive airway 
pressure (CPAP) treatment, involving wearing a mask over 
the nose during sleep to maintain airway patency. CPAP has 





been shown to be a promising treatment for OSA in young 
obese women with PCOS, with improvements in insulin 
sensitivity, daytime diastolic blood pressure, and cardiac 
sympathovagal balance after eight weeks of treatment.176 
These results indicate the need for a larger, well-designed 
randomized controlled trial to assess the clinically relevant 
effects of CPAP treatment on markers of future cardiovascular 
risk in women with PCOS.177
For the general OSA subpopulation (mostly men), there 
is now evidence from systematic reviews with meta-analysis 
that CPAP reduces blood pressure178 and endothelial dysfunc-
tion, which promote the development of atherosclerosis.179,180 
Thus, CPAP could have a role in primary prevention of vascu-
lar disease, despite recent findings that CPAP is not effective 
in reducing coronary events in those with preexisting vascular 
disease.181 Systematic reviews with meta-analysis have also 
indicated that insulin resistance can be improved with CPAP 
use, thereby possibly reducing the risk of development of 
type 2 diabetes in nondiabetic and prediabetic individuals.18
Importantly for women with PCOS, a systematic review 
with meta-analysis has provided evidence that CPAP treat-
ment reduces depressive symptoms.182 A subsequent large, 
randomized controlled trial of over 2000 individuals with 
moderate-to-severe OSA and coronary or cerebrovascular dis-
ease demonstrated that CPAP was effective in increasing QoL 
as well as decreasing symptoms of depression and anxiety.183
The American College of Physicians now recommends 
cognitive behavior therapy (CBT) as the most appropriate 
treatment for all adults with insomnia.184 This treatment is 
also recommended as a first-line treatment for insomnia by the 
British Association for Psychopharmacology.185 The efficacy 
of CBT in treating insomnia symptoms has been demonstrated 
in multiple systematic reviews with meta-analyses,186–189 but 
most sleep clinics do not have clinical psychologists available 
to provide this treatment. In view of the widespread mental 
health and other problems reported among women with PCOS, 
there is a good case for referral to a clinical psychologist who 
can assess and address problems holistically.
In recent years, trials have been undertaken to assess the 
efficacy of online delivery of CBT for insomnia, using highly 
structured internet programs as a means of overcoming the 
barriers to face-to-face delivery of treatment.190 A recent 
systematic review with meta-analysis of 15 randomized 
controlled trials of internet CBT for insomnia found evi-
dence of clinically significant improvements in symptoms, 
of the order achieved in face-to-face CBT.190 Importantly, 
the ISI score of patients was found to be reduced overall 
by 21%,190 and by 15% in a similar systematic review with 
 meta-analysis.191 This option may appeal to women with 
PCOS as cost-effective, but they should still be encouraged 
to consult a clinical psychologist or other professional sup-
port services for wider problems.
There are well-recognized hazards in using pharmaco-
therapy for the primary treatment of insomnia. Depending 
on the type of drug used, negative effects include carry-over 
daytime sedation, slowed reactions and memory impairment, 
as well as the potential for intensification of symptoms upon 
cessation of treatment.173 Pharmacotherapy is only recom-
mended short term.192 This is particularly pertinent for women 
with PCOS whose insomnia and other sleep disturbances are 
unlikely to be short term and are related to underlying factors 
that need to be addressed directly.
Women who experience sleep disturbances, but do not 
meet the criteria for clinical diagnosis of a sleep disorder, 
may benefit from sleep hygiene approaches. This includes 
behavioral and environmental recommendations for promot-
ing sleep.193 Avoidance of smoking and alcohol and regular 
physical activity are aspects of sleep hygiene that have already 
been described. Other recommendations include avoidance 
of caffeine, adhering to regular sleep and wake times and 
stress management.193 Stress management techniques, such 
as mindfulness, have been shown to reduce presleep arousal 
and worry,194 which may be beneficial for women with PCOS. 
Clinical anxiety requires psychological expertise, however.
As has been highlighted throughout this review, it is com-
mon for women with PCOS to experience symptoms that 
span multiple medical specialties. The management of sleep 
disturbances among women with PCOS should form part of 
an interdisciplinary model of care (summarized in Figure 5) 
with effective communication between care providers.195 It 
is important that interdisciplinary care is patient-centered195 
and emphasizes a holistic approach to health and well-being.
Conclusion
There is mounting evidence for an association between 
PCOS and sleep disturbances that is complex and possibly 
bidirectional. This is not simply due to the tendency of women 
with PCOS to be obese, as associations are seen in PCOS 
women of normal weight and most associations are upheld 
after adjustment for BMI. This suggests poor sleep is part of 
the pathophysiology of PCOS. We view PCOS as a condition 
of severe metabolic stress that cascades into oxidative and 
emotional stress. We suggest that multidimensional treat-
ment, including treatment to improve sleep, may improve 
metabolic function and could potentially prevent long-term 
cardiometabolic sequelae for these women.
We have identified some important gaps in the literature, 
with further research recommended. These include a need 
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to fully describe HPA function in women with PCOS, and 
for further trials of insulin sensitizers and interventions 
designed to overcome the specific difficulties that women 
with PCOS have in sustaining physical activity. The impli-
cations for sleep deserve specific attention as well as the 
possibility that bidirectional processes can be harnessed 
so that improved sleep reduces metabolic stress in women 
with PCOS.
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